882 related articles for article (PubMed ID: 29488226)
1. Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3.
Papp KA; Gordon KB; Langley RG; Lebwohl MG; Gottlieb AB; Rastogi S; Pillai R; Israel RJ
Br J Dermatol; 2018 Aug; 179(2):320-328. PubMed ID: 29488226
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis and Skin of Color: Results from the Pooled AMAGINE-2/-3 Randomized Trials.
McMichael A; Desai SR; Qureshi A; Rastogi S; Alexis AF
Am J Clin Dermatol; 2019 Apr; 20(2):267-276. PubMed ID: 30471012
[TBL] [Abstract][Full Text] [Related]
3. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.
Lebwohl M; Strober B; Menter A; Gordon K; Weglowska J; Puig L; Papp K; Spelman L; Toth D; Kerdel F; Armstrong AW; Stingl G; Kimball AB; Bachelez H; Wu JJ; Crowley J; Langley RG; Blicharski T; Paul C; Lacour JP; Tyring S; Kircik L; Chimenti S; Callis Duffin K; Bagel J; Koo J; Aras G; Li J; Song W; Milmont CE; Shi Y; Erondu N; Klekotka P; Kotzin B; Nirula A
N Engl J Med; 2015 Oct; 373(14):1318-28. PubMed ID: 26422722
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase III trials.
Langley RG; Armstrong AW; Lebwohl MG; Blauvelt A; Hsu S; Tyring S; Rastogi S; Pillai R; Israel R
Br J Dermatol; 2019 Feb; 180(2):306-314. PubMed ID: 30328108
[TBL] [Abstract][Full Text] [Related]
5. Complete clearance and Psoriasis Area and Severity Index response for brodalumab and ustekinumab by previous treatment history in AMAGINE-2 and AMAGINE-3.
Reich K; Hansen JB; Puig L; Konstantinou MP; Warren RB
J Eur Acad Dermatol Venereol; 2021 Oct; 35(10):2034-2044. PubMed ID: 34076919
[TBL] [Abstract][Full Text] [Related]
6. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis.
Papp KA; Reich K; Paul C; Blauvelt A; Baran W; Bolduc C; Toth D; Langley RG; Cather J; Gottlieb AB; Thaçi D; Krueger JG; Russell CB; Milmont CE; Li J; Klekotka PA; Kricorian G; Nirula A
Br J Dermatol; 2016 Aug; 175(2):273-86. PubMed ID: 26914406
[TBL] [Abstract][Full Text] [Related]
7. Improvement in itch and other psoriasis symptoms with brodalumab in phase 3 randomized controlled trials.
Gottlieb AB; Gordon K; Hsu S; Elewski B; Eichenfield LF; Kircik L; Rastogi S; Pillai R; Israel R
J Eur Acad Dermatol Venereol; 2018 Aug; 32(8):1305-1313. PubMed ID: 29512200
[TBL] [Abstract][Full Text] [Related]
8. Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator-controlled phase 3 AMAGINE-2 trial.
Puig L; Lebwohl M; Bachelez H; Sobell J; Jacobson AA
J Am Acad Dermatol; 2020 Feb; 82(2):352-359. PubMed ID: 31175909
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
Gordon KB; Strober B; Lebwohl M; Augustin M; Blauvelt A; Poulin Y; Papp KA; Sofen H; Puig L; Foley P; Ohtsuki M; Flack M; Geng Z; Gu Y; Valdes JM; Thompson EHZ; Bachelez H
Lancet; 2018 Aug; 392(10148):650-661. PubMed ID: 30097359
[TBL] [Abstract][Full Text] [Related]
10. Complete clearance and psoriasis area and severity index response for brodalumab and ustekinumab in AMAGINE-2 and -3.
Warren RB; Hansen JB; Reich K; Paul C; Puig L
J Eur Acad Dermatol Venereol; 2021 Feb; 35(2):450-457. PubMed ID: 32662540
[TBL] [Abstract][Full Text] [Related]
11. Brodalumab: A Review in Moderate to Severe Plaque Psoriasis.
Blair HA
Drugs; 2018 Mar; 78(4):495-504. PubMed ID: 29516365
[TBL] [Abstract][Full Text] [Related]
12. Twelve-week secukinumab treatment is consistently efficacious for moderate-to-severe psoriasis regardless of prior biologic and non-biologic systemic treatment: Post hoc analysis of six randomised trials.
Hampton P; Halliday A; Aassi M; Subramanian S; Jain M; Griffiths CEM
J Eur Acad Dermatol Venereol; 2021 Apr; 35(4):928-937. PubMed ID: 33030755
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of brodalumab in the Korean population for the treatment of moderate to severe plaque psoriasis: A randomized, phase III, double-blind, placebo-controlled study.
Seo SJ; Shin BS; Lee JH; Jeong H
J Dermatol; 2021 Jun; 48(6):807-817. PubMed ID: 33373480
[TBL] [Abstract][Full Text] [Related]
14. Comparable efficacy and safety of brodalumab in obese and nonobese patients with psoriasis: analysis of two randomized controlled trials.
Hsu S; Green LJ; Lebwohl MG; Wu JJ; Blauvelt A; Jacobson AA
Br J Dermatol; 2020 Apr; 182(4):880-888. PubMed ID: 31276189
[TBL] [Abstract][Full Text] [Related]
15. Risankizumab vs. ustekinumab for plaque psoriasis: a critical appraisal.
Al-Janabi A; Jabbar-Lopez ZK; Griffiths CEM; Yiu ZZN
Br J Dermatol; 2019 Jun; 180(6):1348-1351. PubMed ID: 30632140
[TBL] [Abstract][Full Text] [Related]
16. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.
Thaçi D; Blauvelt A; Reich K; Tsai TF; Vanaclocha F; Kingo K; Ziv M; Pinter A; Hugot S; You R; Milutinovic M
J Am Acad Dermatol; 2015 Sep; 73(3):400-9. PubMed ID: 26092291
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial.
Langley RG; Tsai TF; Flavin S; Song M; Randazzo B; Wasfi Y; Jiang J; Li S; Puig L
Br J Dermatol; 2018 Jan; 178(1):114-123. PubMed ID: 28635018
[TBL] [Abstract][Full Text] [Related]
18. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
Spuls PI; Hooft L
Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
[TBL] [Abstract][Full Text] [Related]
19. Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis: The UltIMMa-1 and UltIMMa-2 Randomized Clinical Trials.
Augustin M; Lambert J; Zema C; Thompson EHZ; Yang M; Wu EQ; Garcia-Horton V; Geng Z; Valdes JM; Joshi A; Gordon KB
JAMA Dermatol; 2020 Dec; 156(12):1344-1353. PubMed ID: 33052382
[TBL] [Abstract][Full Text] [Related]
20. Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study.
Nakagawa H; Niiro H; Ootaki K;
J Dermatol Sci; 2016 Jan; 81(1):44-52. PubMed ID: 26547109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
